Latest Abatacept Stories
WALTHAM, Mass., Nov. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed U.S.
Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA(R) (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years.
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment.
WALTHAM, Mass., Aug.
Lund, Sweden, June 24, 2008 - Active Biotech AB's (OMX Nordic:ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) has achieved its objectives in a clinical phase IIa trial of the candidate drug RhuDex(R) for the treatment of rheumatoid arthritis.
WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Roche/Chugai's Actemra will be two of the most successful emerging novel agents in the rheumatoid arthritis drug market over the next decade in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Bristol-Myers Squibb has announced positive results from an exploratory Phase II study of 56 individuals that suggested that Orencia, a prescription drug for adults with moderate to severe rheumatoid arthritis, may delay the development of RA in people with undifferentiated inflammatory arthritis.
WASHINGTON, Nov. 14 /PRNewswire-FirstCall/ -- Bri
NEW YORK (Reuters Health) - For rheumatoid arthritis (RA) sufferers who do not get adequate relief from so-called TNF-inhibitors such as etanercept or infliximab, a new drug called Orencia may provide significant clinical and functional benefits, according to a study published this week.
- A serpent whose bite was fabled to produce intense thirst.